|
Marc Zabeau (born Lier, 1949) is a Belgian scientist and businessman. == Biography == Marc Zabeau graduated in 1971 as a licentiate in zoology at the University of Ghent and obtained a PhD in 1974, studying the genetics of ''Escherichia coli'' in the lab of Jeff Schell. In 1976, on an NFWO scholarship as a Fulbright Hayes postdoctoral fellow, he went for two years to the Cold Spring Harbor Laboratory in New York, the United States. From 1978 until 1983 he worked at the European Molecular Biology Laboratory in Heidelberg, Germany. during his stay in Heidelberg, he was appointed as professor of genetic engineering at the Vrije Universiteit Brussel. In 1983, he became director of research of Plant Genetic Systems in Ghent, Belgium and in 1986 director of intellectual property and business development. He founded several biotech companies, such as Helix C.V. (Ghent, 1988), KeyeGene N.V. (Wageningen, 1989), GenScope Inc. (United States, 1995) and Methexis (Ghent, 1997). In 1999, he succeeded Marc Van Montagu as scientific director of the Department of Plant Systems Biology at the Flanders Institute for Biotechnology (VIB). In 2002, he was succeeded by Dirk Inzé. In 1999, he was appointed as full-time professor of genome biology and functional genomics at the University of Ghent. Zabeau was formerly CEO of Trinean. He is currently general manager of Ghent University's TechTransfer,〔http://www.techtransfer.ugent.be/〕 and managing partner of Qbic Venture Partners.〔http://qbic.be/team/marc-zabeau/〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Marc Zabeau」の詳細全文を読む スポンサード リンク
|